Abstract:Background: As the muscular and connective tissue components of the vagina are estrogen responsive, clinicians may recommend vaginal estrogen to optimize tissues preoperatively and as a possible means to reduce prolapse recurrence, but long-term effects of perioperative intravaginal estrogen on surgical prolapse management are uncertain. Objective: This study aimed to compare the efficacy of perioperative vaginal estrogen vs placebo cream in reducing composite surgical treatment failure 36 months after native tissue transvaginal prolapse repair. Study design: This was an extended follow-up of a randomized superiority trial conducted at 3 tertiary US sites. Postmenopausal patients with bothersome anterior or apical vaginal prolapse were randomized 1:1 to 1-g conjugated estrogen cream (0.625 mg/g) or placebo, inserted vaginally twice weekly for ≥5 weeks preoperatively and continued twice weekly for 12 months postoperatively. All participants underwent vaginal hysterectomy (if the uterus was present) and standardized uterosacral or sacrospinous ligament suspension at the surgeon's discretion. The primary report's outcome was time to failure by 12 months postoperatively, defined by a composite outcome of objective prolapse of the anterior or posterior walls beyond the hymen or the vaginal apex descending below one-third the total vaginal length, subjective bulge symptoms, and/or retreatment. After 12 months, participants could choose to use-or not use-vaginal estrogen for atrophy symptom bother. The secondary outcomes included Pelvic Organ Prolapse Quantification points, subjective prolapse symptom severity using the Patient Global Impression of Severity and the Patient Global Impression of Improvement, and prolapse-specific subscales of the 20-Item Pelvic Floor Distress Inventory and the Pelvic Floor Impact Questionnaire-Short Form 7. Data were analyzed as intent to treat and "per protocol" (ie, ≥50% of expected cream use per medication diary). Results: Of 206 postmenopausal patients, 199 were randomized, and 186 underwent surgery. Moreover, 164 postmenopausal patients (88.2%) provided 36-month data. The mean age was 65.0 years (standard deviation, 6.7). The characteristics were similar at baseline between the groups. Composite surgical failure rates were not significantly different between the estrogen group and the placebo group through 36 months, with model-estimated failure rates of 32.6% (95% confidence interval, 21.6%-42.0%) and 26.8% (95% confidence interval, 15.8%-36.3%), respectively (adjusted hazard ratio, 1.55; 95% confidence interval, 0.90-2.66; P=.11). The results were similar for the per-protocol analysis. Objective failures were more common than subjective failures, combined objective and subjective failures, or retreatment. Using the Patient Global Impression of Improvement, 75 of 80 estrogen participants (94%) and 72 of 76 placebo participants (95%) providing 36-month data reported that they were much or very much better 36 months after surgery (P>.99). These data included reports from 51 of 55 "surgical failures." Pelvic Organ Prolapse Quantification measurements, Patient Global Impression of Severity scores, and prolapse subscale scores of the 20-Item Pelvic Floor Distress Inventory and Pelvic Floor Impact Questionnaire-Short Form 7 all significantly improved for both the estrogen and placebo groups from baseline to 36 months postoperatively without differences between the groups. Of the 160 participants providing data on vaginal estrogen usage at 36 months postoperatively, 40 of 82 participants (49%) originally assigned to the estrogen group were using prescribed vaginal estrogen, and 47 of 78 participants (60%) assigned to the placebo group were using vaginal estrogen (P=.15). Conclusion: Adjunctive perioperative vaginal estrogen applied ≥5 weeks preoperatively and 12 months postoperatively did not improve surgical success rates 36 months after uterosacral or sacrospinous ligament suspension prolapse repair. Patient perception of improvement remained very high at 36 months.

Regarding "Outcomes of vaginal repair and vaginal repair combined with GnRHa administration in the treatment of cesarean section scar defects: A randomized clinical trial"

Outcomes of vaginal repair and vaginal repair combined with GnRHa administration in the treatment of cesarean section scar defects: A randomized clinical trial

[Clinical Comparative Analysis of Surgical Resection of the Pregnancy by Hysterotomy and Hysterectomy for Cesarean Scar Pregnancy].

Obstetrical outcomes after vaginal repair of caesarean scar diverticula in reproductive-aged women

A Prediction Model for the Efficacy of Transvaginal Repair in Patients with Cesarean Scar Defect: an Evidence-Based Proposal for Patient Selection.

Prospective Evaluation of Five Methods Used to Treat Cesarean Scar Defects.

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Hysteroscopic Electric Resection Versus Vaginal Surgery in the Treatment of Uterine Scar Defects after Cesarean Section

Three-year outcomes of a randomized clinical trial of perioperative vaginal estrogen as adjunct to native tissue vaginal apical prolapse repair

A comparison of the effects of two different treatment methods on cesarean section scar diverticulum : the surgical repair of cesarean scars via combined laparoscopy and hysteroscopy vs . cyclic estrogen / progesterone therapy

Analysis of high risk factors for complications in the trial of vaginal delivery due to uterine scarring in a subsequent pregnancy to a cesarean section.

Efficacy of Caesarean Scar Defect Repair in Improving Postmenstrual Bleeding and Factors Associated with Poor Effect

Efficacy comparison of two different treatments to cesarean section scar diverticulum:scar excision and repair by laparoscopy combined hysteroscopy and progesterone cycle therapy

The association of endometrial closure during cesarean section to the risk of developing uterine scar defect: a randomized control trial

Comparison of two different methods for cervicovaginal reconstruction: a long-term follow-up

A Comparison of Transvaginal Removal and Repair of Uterine Defect for Type II Cesarean Scar Pregnancy and Uterine Artery Embolization Combined With Curettage

Study on Comparison of Clinical Effects of Two Kinds of Operational Procedures in Treatment of Heavy Rectocele.

Effect of Mifepristone Preconditioning on Stress Response and Sex Hormone Levels after Combined Laparoscopic Treatment for Cesarean Scar Pregnancy: A Prospective Randomized Trial

Comparison of the surgical outcomes between paravaginal repair and anterior colporrhaphy: A retrospective case-control study

Evaluating resectoscopy and the levonorgestrel intrauterine system for intermenstrual bleeding associated with cesarean scar defects: A retrospective study of treatment outcomes

Vaginal Reinforcement of Cesarean Section Scar for Cesarean Scar Pregnancy

A randomized clinical trial of the impact of local estrogen on postoperative tissue quality after vaginal reconstructive surgery